Work

The proportion of patients achieving low biomarker levels with tezepelumab treatment in the phase 3 NAVIGATOR study

Year: 2023

Type: conference-abstract

DOI: 10.1183/13993003.congress-2023.oa1418

Authors: David J Jackson, Ian D Pavord, J Christian Virchow, Jane R Parnes, Amgad Gamil, Gillian Hunter, Sandhia Ponnarambil, Neil Martin, Michael E Wechsler

Institutions: Guy's Hospital, King's College London, Guy's and St Thomas' NHS Foundation Trust, National Institute for Health and Care Research, University of Oxford, Universitätsmedizin Rostock, University of Rostock, Amgen (United States), AstraZeneca (United Kingdom), University of Leicester, NIHR Leicester Biomedical Research Centre, National Jewish Health

Language: English

Topic: Asthma and respiratory diseases

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4387980280

Cites:

Cited by: 2

Related to: 10